Terence Flynn
Stock Analyst at Morgan Stanley
(3.97)
# 494
Out of 4,829 analysts
190
Total ratings
54.46%
Success rate
8.27%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Equal-Weight | $12 → $11 | $6.61 | +66.41% | 9 | May 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $24 → $22 | $8.28 | +165.70% | 6 | May 9, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $140 → $132 | $92.87 | +42.14% | 3 | May 6, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $15 → $10 | $8.71 | +14.81% | 10 | May 5, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $346 → $348 | $301.42 | +15.45% | 9 | May 1, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $241 → $250 | $184.60 | +35.43% | 16 | Apr 28, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $164 → $169 | $154.22 | +9.58% | 21 | Apr 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,146 → $1,124 | $734.57 | +53.01% | 19 | Apr 9, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $328 → $330 | $265.86 | +24.13% | 6 | Apr 9, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $69 → $63 | $20.24 | +211.26% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $35.62 | -10.16% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $113 → $106 | $75.97 | +39.53% | 16 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $9.50 | +78.95% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $8.12 | +35.47% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $39 | $46.45 | -16.04% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $22.28 | +39.14% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $25.57 | +361.48% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $5.03 | +615.71% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $33.15 | +53.85% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $97.17 | +72.89% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $1.47 | +444.22% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $118.17 | +268.96% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $251.15 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.31 | - | 1 | Jul 21, 2017 |
Arvinas
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $6.61
Upside: +66.41%
Arcus Biosciences
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $8.28
Upside: +165.70%
BioNTech SE
May 6, 2025
Maintains: Overweight
Price Target: $140 → $132
Current: $92.87
Upside: +42.14%
Organon & Co.
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $8.71
Upside: +14.81%
United Therapeutics
May 1, 2025
Maintains: Equal-Weight
Price Target: $346 → $348
Current: $301.42
Upside: +15.45%
AbbVie
Apr 28, 2025
Maintains: Overweight
Price Target: $241 → $250
Current: $184.60
Upside: +35.43%
Johnson & Johnson
Apr 16, 2025
Maintains: Equal-Weight
Price Target: $164 → $169
Current: $154.22
Upside: +9.58%
Eli Lilly and Company
Apr 9, 2025
Maintains: Overweight
Price Target: $1,146 → $1,124
Current: $734.57
Upside: +53.01%
Amgen
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $328 → $330
Current: $265.86
Upside: +24.13%
Biohaven
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $20.24
Upside: +211.26%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $35.62
Upside: -10.16%
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $75.97
Upside: +39.53%
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $9.50
Upside: +78.95%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $8.12
Upside: +35.47%
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $46.45
Upside: -16.04%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $22.28
Upside: +39.14%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $25.57
Upside: +361.48%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $5.03
Upside: +615.71%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $33.15
Upside: +53.85%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $97.17
Upside: +72.89%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $1.47
Upside: +444.22%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $118.17
Upside: +268.96%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $251.15
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -